New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amisulpride 50mg;   - tablet - 50 mg - active: amisulpride 50mg   excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; methylcellulose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; methylcellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; sodium starch glycollate type a; methylcellulose; magnesium stearate; macrogol 6000; microcrystalline cellulose; lactose monohydrate; purified talc; basic butylated methacrylate copolymer - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; hypromellose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.